卵巢支持间质细胞肿瘤保留生育功能治疗的预后及相关因素

doi:10.6040/j.issn.1671-7554.0.2018.223

摘要/Abstract

摘要： 目的探讨卵巢支持间质细胞肿瘤(SLCT)患者保留生育功能治疗的预后及其相关因素。方法回顾性分析北京协和医院52例保留生育功能治疗的卵巢SLCT患者的生存率、复发、死亡与生育状况等。结果临床表现中,41例有高雄激素表现,11例无内分泌表现。全部肿瘤均位于单侧卵巢;肿瘤最大径线2~34 cm,平均10 cm;Ⅰ期50例(ⅠA期36例,ⅠC期14例),ⅢC期1例,分期不明1例;高分化4例(7.7%),中分化14例(26.9%),低分化34例(65.4%),低分化者中含有网状结构者9例、含异源成分者4例。初次手术方式包括仅行肿瘤剔除6例(11.5%),患侧附件切除36例(69.2%),全面分期手术10例(19.2%)。初治术后29例接受化疗1~4个疗程。平均随访72个月,6例复发,3例死亡。预后差与无内分泌表现、肿瘤大、分期高于ⅠA期有关,与低分化、网型或异源成分可能相关,与手术方式及术后是否化疗无关。结论卵巢SLCT是一种少见的卵巢性索间质肿瘤,多数患者以男性化临床表现和盆腔包块为特征,无内分泌表现者恶性程度较高,预后与肿瘤大小、临床分期有关,与组织分化程度可能相关。年轻患者可采取保留生育功能的手术,对有高危因素及复发患者建议术后辅助化疗并长期随访。

关键词: 卵巢支持间质细胞肿瘤, 保留生育功能治疗, 预后

Abstract: Objective To evaluate the prognosis and its related factors of patients with ovarian Sertoli-Leydig cell tumor(SLCT)after fertility-preserving surgery. Methods Detail clinical data, including survival rates, recurrence, death and fertility states, of 52 SLCT patients after fertility-preserving surgery in Peking Union Medical College Hospital were retrospectively reviewed. Results Forty-one cases showed androgenic manifestations, while 11 cases had no endocrine symptoms. All tumors located in unilaterl ovary; the mean tumor diameter was 10.0 cm(range 2-34 cm); fifty cases were at stage Ⅰ(36 cases at stage ⅠA, 14 cases at stage ⅠC), one was at stage ⅢC, ones stage was unknown; four(7.7%)tumors were well differentiated, 14(26.9%)were intermediately differentiated, 34(65.4%)were poorly differentiated. In the poorly differentiated tumors, 9 had a retiform pattern, 4 had heterologous elements. Six patients(11.5%)underwent cystectomy, 36(69.2%)underwent unilateral salpingo-oophorectomy, and 10(19.2%)underwent standard staging surgery. Twenty-nine patients received systematic chemotherapy(1-4 courses of treatment)after 山东大学学报 (医学版)56卷5期 -杨旎,等.卵巢支持间质细胞肿瘤保留生育功能治疗的预后及相关因素 \=-the initial surgery. The average follow-up period was 72 months; six cases recurred, in whom 3 cases died. The poor prognosis was correlated with no endocrine symptoms, bigger tumor size, clinical stage >ⅠA, and probably correlated with poor differentiation, retiform pattern and heterologous elements, while not correlated with surgery type and postoperative chemotherapy. Conclusion SLCT is a rare type of sex cord-stromal tumor of the ovary. Most SLCT patients have androgenic manifestations and abdominal masses, and tumors without endocrine changes may indicate more aggressive biological behaviors. The prognosis is correlated with tumor size and clinical stage, and probably correlated with the degree of differentiation. Conservative surgery is acceptable for young patients wishing to preserve fertility, and postoperative adjuvant chemotherapy and long-term follow up are recommended to those with high-risk factors of recurrence.

Key words: Ovarian Sertoli-Leydig cell tumor, Fertility-preserving therapy, Prognosis

中图分类号:

R711.75

杨旎,曹冬焱,杨佳欣,游燕,沈铿. 卵巢支持间质细胞肿瘤保留生育功能治疗的预后及相关因素[J]. 山东大学学报 (医学版), 2018, 56(5): 30-34.

YANG Ni, CAO Dongyan, YANG Jiaxin, YOU Yan, SHEN Keng. Prognosis related factors of patients with ovarian Sertoli-Leydig cell tumor after fertility-preserving surgery[J]. Journal of Shandong University (Health Sciences), 2018, 56(5): 30-34.

参考文献

[1] Lantzsch T, Stoerer S, Lawrenz K, et al. Sertoli-Leydig cell tumor[J]. Arch Gynecol Obstet, 2001, 264(4): 206-208.
[2] Young RH, Scully RE. Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases[J]. Am J Surg Pathol, 1985, 9(8): 543-569.
[3] Shu H, Yang X, Gao AF. Ovarian Sertoli-Leydig cell tumor in a 9-month-old infant with special histologic pattern[J]. Fetal Pediatr Pathol, 2012, 31(6): 388-393.
[4] Bhat RA, Lim YK, Chia YN, et al. Sertoli-Leydig cell tumor of the ovary: analysis of a single institution database[J]. J Obstet Gynaecol Res, 2013, 39(1): 305-310.
[5] Weng CS, Chen MY, Wang TY, et al. Sertoli-Leydig cell tumors of the ovary: a Taiwanese Gynecologic Oncology Group study[J]. Taiwan J Obstet Gynecol, 2013, 52(1): 66-70.
[6] Abu-Zaid A, Azzam A, Alghuneim LA, et al. Poorly differentiated ovarian sertoli-leydig cell tumor in a 16-year-old single woman: a case report and literature review[J]. Case Rep Obstet Gynecol, 2013: 858501.
[7] Chang RJ, Dumesic DA. Polycystic ovary syndrome and hyperandrogenic states. In: Yen, Samuel SC, ed. Yen & Jaffes reproductive endocrinology[M]. 5th ed. Philadelphia: Elsevier Saunders, 2004: 597-632.
[8] 肖会廷,李斌,李晓光,等.卵巢支持莱迪细胞瘤15例临床病理分析[J].实用妇产科杂志, 2011, 27(12): 933-936. XIAO Huiting, LI Bin, LI Xiaoguang, et al. Ovarian Sertoli-Leydig cell tumors: clinical pathologic features of 15 cases[J]. J Practical Obstet Gynecol, 2011, 27(12): 933-936.
[9] Chen L, Tunnell CD, De Petris G. Sertoli-Leydig cell tumor with heterologous element: a case report and a review of the literature[J]. Int J Clin Exp Pathol, 2014, 7(3): 1176-1181.
[10] Roth LM, Anderson MC, Govan AD, et al. Sertoli-Leydig cell tumors: a clinicopathologic study of 34 cases[J]. Cancer, 1981, 48(1): 187-197.
[11] Grove A, Vestergaard V. Ovarian Sertoli-Leydig cell tumor of intermediate grade with heterologous elements of rhabdomyosarcoma. A case report and a review of the literature[J]. Ann Diagn Pathol, 2006, 10(5): 288-293.
[12] Liggins CA, Ma LT, Schlumbrecht MP. Sertoli-Leydig cell tumor of the ovary: a diagnostic dilemma[J]. Gynecol Oncol Rep, 2015, 15: 16-19.
[13] Zhang M, Cheung MK, Shin JY, et al. Prognostic factors responsible for survival in sex-cord stromal tumors of the ovary—an analysis of 376 women[J]. Gynecol Oncol, 2007, 104(2): 396-400.
[14] Schneider DT, Harms D, Calaminus G. Ovarian sex cord stromal tumors in children and adolescents[J]. J Reprod Med, 2005, 50(6): 439-446.
[15] Appetecchia M, Cela V Bernardi F, Burelli A, et al. Sertoli-Leydig cell androgens-estrogens secreting tumor of the ovary: ultra-conservnive surgery[J]. Eur J Obstet Gynecol Reprod Biol, 2004, 116(1): 113-116.
[16] Sahoo TK, Kar T, Kar A, et al. Poorly differentiated Sertoli-Leydig cell tumour of ovary with heterologous elements[J]. J Clin Diagn Res, 2017, 11(5): XD01-XD02.
[17] Sigismondi C, Gadducci A, Lorusso D, et al. Ovarian Sertoli-Leydig cell tumors. A retrospective MITO study[J]. Gynecol Oncol, 2012, 125(3): 673-676.
[18] Litta P, Saccardi C, Conte L, et al. Sertoli-Leydig cell tumors: current status of surgical management: literature review and proposal of treatment[J]. Gynecol Endocrinol, 2013, 29(5): 412-417.

相关文章 15

[1]	郑苏,陈述花,李华,邓劼,陈春红,王晓慧,冯卫星,韩萧迪,张雨佳,李娜,李莫,方方. 脑电变化和BASED评分与54例婴儿痉挛症促肾上腺皮质激素疗效的相关性[J]. 山东大学学报 (医学版), 2022, 60(9): 91-96.
[2]	王丽慧,高敏,孔北华. 子宫血管肉瘤2例报告并文献复习[J]. 山东大学学报 (医学版), 2022, 60(9): 108-112.
[3]	高中霞,张铭,樊明德,谭晨阳,王梦迪,王超,樊跃飞,丁守銮,王成伟. 伽玛刀治疗81例肺癌脑转移瘤的疗效及预后因素[J]. 山东大学学报 (医学版), 2022, 60(8): 44-49.
[4]	贺士卿,李皖皖,董书晴,牟婧怡,刘宇莹,魏思雨,刘钊,张家新. 基于数据库构建乳腺癌焦亡相关基因的预后风险模型[J]. 山东大学学报 (医学版), 2022, 60(8): 34-43.
[5]	张玉凤,徐敏,邢秀丽,逄曙光,户克庆. 689例非ST段抬高型心肌梗死患者的临床流行病学特征[J]. 山东大学学报 (医学版), 2022, 60(7): 118-122.
[6]	李琳琳,王凯. 基于生物信息学预测肝细胞癌预后基因[J]. 山东大学学报 (医学版), 2022, 60(5): 50-58.
[7]	郑昊天,王光辉,赵小刚,王亚东,曾榆凯,杜贾军. 基于数据库LKB1突变肺腺癌DNA异常甲基化位点构建的预后风险模型[J]. 山东大学学报 (医学版), 2022, 60(3): 51-58.
[8]	陈立晓,英信江,陈歆维,王菲,孙臻峰,董频. 下咽鳞癌蛋白质谱鉴定及预后靶分子筛选[J]. 山东大学学报 (医学版), 2021, 59(9): 140-147.
[9]	褚晏,刘端瑞,朱文帅,樊荣,马晓丽,汪运山,郏雁飞. DNA甲基化转移酶在胃癌中的表达及其临床意义[J]. 山东大学学报 (医学版), 2021, 59(7): 1-9.
[10]	陈丽宇,肖娟,吕仙忠,段宝敏,洪凡真. 影响孕产妇下肢深静脉血栓预后的危险因素分析[J]. 山东大学学报 (医学版), 2021, 59(7): 38-42.
[11]	田瑶天,王宝,李叶琴,王滕,田力文,韩波,王翠艳. 基于可解释性心脏磁共振参数的机器学习模型预测儿童心肌炎的预后[J]. 山东大学学报 (医学版), 2021, 59(7): 43-49.
[12]	李皖皖,周文凯,董书晴,贺士卿,刘钊,张家新,刘斌. 利用数据库信息构建乳腺癌免疫关联lncRNAs风险评估模型[J]. 山东大学学报 (医学版), 2021, 59(7): 74-84.
[13]	米琦,史爽,李娟,李培龙,杜鲁涛,王传新. 膀胱癌circRNAs介导的ceRNA网络及预后评估模型的构建[J]. 山东大学学报 (医学版), 2021, 59(6): 94-102.
[14]	谢同辉,陈志强,常建华,赵丹文,徐博文,智绪亭. 肝内胆管癌根治性切除术后生存因素分析及列线图的建立[J]. 山东大学学报 (医学版), 2021, 59(4): 93-99.
[15]	李湘青,殷欣,赵雪莲,赵培庆. NK细胞亚群CD56^bright在帕金森患者外周血中的表达及临床意义[J]. 山东大学学报 (医学版), 2021, 59(2): 34-40.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed